New Research: Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders: Aim In a recent… #Endocrinology #Endo http
RT @PiemontiL: Our trial on LDX for new-onset T1D showed no benefit in preserving beta cell. But post hoc analysis discovered a glimmer of…
Our trial on LDX for new-onset T1D showed no benefit in preserving beta cell. But post hoc analysis discovered a glimmer of hope. Endometabolic & immunologic factors may hold the key. Further research required #Type1Diabetes #diabetesresearch #DRIMila